Model Informed Drug Development Archives | Certara

White Paper

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Replace TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA. Learn more…

Certara2025 年 10 月 3 日

Dizal Pharma

Case Study

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…

Certara2025 年 10 月 2 日

Conference

37th Annual Meeting of the Southern California Chapter Society of Toxicology (SCCSOT)

Certara2025 年 9 月 22 日

Announcement

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – 2025 年 9 月 17 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in…

Certara2025 年 9 月 17 日

Guide

The Top 10 Things You Need to Know About ADNCA Datasets

Learn how ADNCA datasets can modernize non-compartmental analysis: enhanced compliance, automations, and faster PK data…

Certara2025 年 9 月 11 日

Conference

Redefining Every Stage of Investment (RESI) Seed to Exit

Certara2025 年 9 月 5 日

Conference

The Pharmacometrics Africa Conference 2025 (PMXAC-2025)

Certara2025 年 9 月 4 日

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

Certara2025 年 9 月 4 日

Webinar

The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape

Certara2025 年 9 月 3 日

Webinar

设计高价值药物研发计划：From Concept to First-in-Human (FIH)

Danielle Pillsbury2025 年 8 月 29 日

© 2025 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software